Phase II Study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS10586-TPS10586
Keyword(s):
Phase Ii
◽
2016 ◽
Vol 34
(15_suppl)
◽
pp. 11053-11053
◽